

Julien Dumurgier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8172525/publications.pdf>

Version: 2024-02-01

117
papers

4,496
citations

94269

37
h-index

123241

61
g-index

126
all docs

126
docs citations

126
times ranked

6180
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Slow walking speed and cardiovascular death in well functioning older adults: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2009, 339, b4460-b4460. | 2.4 | 274 |
| 2 | Association of sleep duration in middle and old age with incidence of dementia. <i>Nature Communications</i> , 2021, 12, 2289. | 5.8 | 254 |
| 3 | Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471. | 4.5 | 204 |
| 4 | Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. <i>Ageing Research Reviews</i> , 2017, 35, 63-73. | 5.0 | 182 |
| 5 | Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study. <i>BMJ: British Medical Journal</i> , 2018, 362, k2927. | 2.4 | 150 |
| 6 | Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study. <i>Lancet Public Health</i> , The, 2020, 5, e42-e50. | 4.7 | 147 |
| 7 | Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2 γ pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 885-896. | 1.8 | 139 |
| 8 | Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1640. | 3.8 | 135 |
| 9 | Prevalence of amyloid β pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740. | 2.8 | 132 |
| 10 | The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 41. | 3.0 | 121 |
| 11 | Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. <i>BMJ: British Medical Journal</i> , 2019, 366, 14414. | 2.4 | 117 |
| 12 | Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. <i>Neurobiology of Aging</i> , 2017, 59, 220.e1-220.e9. | 1.5 | 116 |
| 13 | Cerebrospinal fluid amyloid β 42/40 ratio in clinical setting of memory centers: a multicentric study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 30. | 3.0 | 101 |
| 14 | SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. <i>Molecular Psychiatry</i> , 2016, 21, 831-836. | 4.1 | 96 |
| 15 | Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. <i>Neurology</i> , 2016, 87, 920-926. | 1.5 | 86 |
| 16 | Seizures in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2016, 87, 912-919. | 1.5 | 81 |
| 17 | Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767. | 0.4 | 81 |
| 18 | Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1451-1459. | 1.2 | 80 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 151-161. | 1.4 | 75 |
| 20 | Gait Speed and Decline in Gait Speed as Predictors of Incident Dementia. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, glw110. | 1.7 | 74 |
| 21 | Hypertension and lower walking speed in the elderly: the Three-City study. <i>Journal of Hypertension</i> , 2010, 28, 1506-1514. | 0.3 | 73 |
| 22 | Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. <i>Alzheimer's and Dementia</i> , 2013, 9, 406-413. | 0.4 | 63 |
| 23 | MRI atrophy of the caudate nucleus and slower walking speed in the elderly. <i>NeuroImage</i> , 2012, 60, 871-878. | 2.1 | 62 |
| 24 | The association of APOE ϵ 4 with cognitive function over the adult life course and incidence of dementia: 20-year follow-up of the Whitehall II study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 5. | 3.0 | 60 |
| 25 | Relevance of A β 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 138. | 1.7 | 59 |
| 26 | Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2. | | 58 |
| 27 | Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. <i>Journal of Neurology</i> , 2014, 261, 144-151. | 1.8 | 56 |
| 28 | Restless legs syndrome is frequently overlooked in patients being evaluated for polyneuropathies. <i>European Journal of Neurology</i> , 2007, 14, 788-792. | 1.7 | 54 |
| 29 | Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2019, 78, 178-185. | 1.5 | 54 |
| 30 | Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2012, 71, 829-835. | 0.7 | 52 |
| 31 | PKR involvement in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 83. | 3.0 | 52 |
| 32 | Impact of the 2008-2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 297-305. | 1.2 | 51 |
| 33 | Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. <i>Neurology</i> , 2020, 95, e953-e961. | 1.5 | 50 |
| 34 | Motor function in the elderly. <i>Neurology</i> , 2013, 81, 417-426. | 1.5 | 48 |
| 35 | Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e53587. | 1.1 | 46 |
| 36 | Epidemiology of neurological diseases in older adults. <i>Revue Neurologique</i> , 2020, 176, 642-648. | 0.6 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Sex differences and the role of education in cognitive ageing: analysis of two UK-based prospective cohort studies. <i>Lancet Public Health</i> , The, 2021, 6, e106-e115. | 4.7 | 45 |
| 38 | A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 38. | 3.0 | 44 |
| 39 | Change in Fast Walking Speed Preceding Death: Results From a Prospective Longitudinal Cohort Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 354-362. | 1.7 | 41 |
| 40 | Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289. | 3.9 | 39 |
| 41 | Risk prediction models for dementia: role of age and cardiometabolic risk factors. <i>BMC Medicine</i> , 2020, 18, 107. | 2.3 | 38 |
| 42 | Biomarkers and acute brain injuries: interest and limits. <i>Critical Care</i> , 2014, 18, 220. | 2.5 | 37 |
| 43 | Healthy behaviors at age 50 years and frailty at older ages in a 20-year follow-up of the UK Whitehall II cohort: A longitudinal study. <i>PLoS Medicine</i> , 2020, 17, e1003147. | 3.9 | 34 |
| 44 | Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 123. | 3.0 | 33 |
| 45 | Inverse association between CSF A β 42 levels and years of education in mild form of Alzheimer's disease: The cognitive reserve theory. <i>Neurobiology of Disease</i> , 2010, 40, 456-459. | 2.1 | 30 |
| 46 | Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. <i>HIV Medicine</i> , 2013, 14, 311-315. | 1.0 | 29 |
| 47 | Association between kidney function and incidence of dementia: 10-year follow-up of the Whitehall II cohort study. <i>Age and Ageing</i> , 2022, 51, . | 0.7 | 29 |
| 48 | Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1459-1471. | 1.2 | 28 |
| 49 | Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879. | 0.4 | 26 |
| 50 | A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. <i>Neuroscience</i> , 2019, 420, 136-144. | 1.1 | 25 |
| 51 | Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 905-913. | 1.2 | 21 |
| 52 | CSF A β 1-42 Levels and Glucose Metabolism in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 845-851. | 1.2 | 20 |
| 53 | Lipid-Lowering Drugs Associated With Slower Motor Decline in the Elderly Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 199-206. | 1.7 | 20 |
| 54 | CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 88. | 3.0 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Emotional memory enhancement in respect of positive visual stimuli in Alzheimer's disease emerges after rich and deep encoding. <i>Cortex</i> , 2015, 65, 89-101. | 1.1 | 19 |
| 56 | CSF level of β -amyloid peptide predicts mortality in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 29. | 3.0 | 19 |
| 57 | Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 27. | 3.0 | 18 |
| 58 | Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β -amyloid peptide and tau. <i>PLoS ONE</i> , 2019, 14, e0217026. | 1.1 | 18 |
| 59 | What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. <i>BMJ Open</i> , 2019, 9, e026380. | 0.8 | 17 |
| 60 | Terminal decline in objective and self-reported measures of motor function before death: 10 year follow-up of Whitehall II cohort study. <i>BMJ</i> , 2021, 374, n1743. | 3.0 | 17 |
| 61 | Hyperuricemia, Gout, and the Brain: an Update. <i>Current Rheumatology Reports</i> , 2021, 23, 82. | 2.1 | 17 |
| 62 | How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663. | 0.8 | 16 |
| 63 | Impact of recommendations on the initial therapy of Parkinson's disease: A population-based study in France. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 543-546. | 1.1 | 14 |
| 64 | Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. <i>Neurobiology of Disease</i> , 2013, 54, 486-491. | 2.1 | 14 |
| 65 | Diagnosis associated with Tau higher than 1200 pg/mL: Insights from the clinical and laboratory practice. <i>Clinica Chimica Acta</i> , 2019, 495, 451-456. | 0.5 | 13 |
| 66 | Timeline of pain before dementia diagnosis: a 27-year follow-up study. <i>Pain</i> , 2021, 162, 1578-1585. | 2.0 | 13 |
| 67 | Time Orientation and 10 Years Risk of Dementia in Elderly Adults: The Three-City Study. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1411-1418. | 1.2 | 12 |
| 68 | Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, . | 3.0 | 12 |
| 69 | The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. <i>Journal of Neurology</i> , 2014, 261, 1187-1195. | 1.8 | 11 |
| 70 | Blood-Based Kinase Assessments in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 338. | 1.7 | 11 |
| 71 | Association of APOE ϵ 4 with cerebral gray matter volumes in non-demented older adults: The MEMENTO cohort study. <i>NeuroImage</i> , 2022, 250, 118966. | 2.1 | 11 |
| 72 | Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 168. | 1.1 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | The role of attention in emotional memory enhancement in pathological and healthy aging. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 434-454. | 0.8 | 10 |
| 74 | Increased Cerebrospinal Fluid Tau Levels in Logopenic Variant of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 611-616. | 1.2 | 9 |
| 75 | Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders. Journal of Alzheimer's Disease, 2018, 64, 889-897. | 1.2 | 9 |
| 76 | Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911. | 1.2 | 9 |
| 77 | New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease. BMC Neuroscience, 2012, 13, 84. | 0.8 | 8 |
| 78 | Frontotemporal dementia is the leading cause of $\Delta^{24}/T+$ profiles defined with $\Delta^{24}/40$ ratio. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 161-169. | 1.2 | 8 |
| 79 | [¹⁸ F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer's disease. European Journal of Neurology, 2021, 28, 1511-1519. | 1.7 | 8 |
| 80 | Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. Alcoholism: Clinical and Experimental Research, 2021, 45, 561-565. | 1.4 | 8 |
| 81 | A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology, 2022, 99, . | 1.5 | 8 |
| 82 | Muscle magnetic resonance imaging sensitivity does not decrease in chronic, mild, or proximal lower limb neuropathies. Muscle and Nerve, 2012, 45, 659-667. | 1.0 | 7 |
| 83 | Screening for cognitive and affective dysfunction in patients suspected of mild cognitive impairment. International Journal of Geriatric Psychiatry, 2014, 29, 936-942. | 1.3 | 7 |
| 84 | Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research and Therapy, 2020, 12, 168. | 3.0 | 7 |
| 85 | Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review. Diagnostics, 2021, 11, 754. | 1.3 | 7 |
| 86 | Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 7 |
| 87 | Relationship between blood pressure, cognitive function and education level in elderly patients with diabetes: A preliminary study. Diabetes and Metabolism, 2013, 39, 418-423. | 1.4 | 6 |
| 88 | Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700. | 0.7 | 5 |
| 89 | Brain Glucose Metabolism in Cerebral Amyloid Angiopathy. Stroke, 2021, 52, 1478-1482. | 1.0 | 3 |
| 90 | Telemedicine in French Memory Clinics During the COVID-19 Pandemic. Journal of Alzheimer's Disease, 2022, 86, 525-530. | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109. | | 2 |
| 92 | Gait Decline. Hypertension, 2015, 66, 263-264. | 1.3 | 2 |
| 93 | O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545. | 0.4 | 2 |
| 94 | Clinical features related to CSF level of amyloid AÎ²42 and AÎ²40 proteins in presence of lobar microbleeds. Revue Neurologique, 2020, 176, 864-867. | 0.6 | 2 |
| 95 | Comparison of the predictive accuracy of multiple definitions of cognitive impairment for incident dementia: a 20-year follow-up of the Whitehall II cohort study. The Lancet Healthy Longevity, 2021, 2, e407-e416. | 2.0 | 2 |
| 96 | O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P267-P267. | | 1 |
| 97 | The Diagnostic Value of a Short Memory Test: The TNI-93. Journal of Alzheimer's Disease, 2021, , 1-11. | 1.2 | 1 |
| 98 | Biomarqueurs du liquide cÃ©rÃ©brospinal dans la maladie d'Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 307-320. | 0.0 | 1 |
| 99 | P1-129: CSF AD BIOMARKERS IN MEMORY CLINIC PATIENTS: THE EP.L.M.FR STUDY. , 2014, 10, P347-P347. | | 0 |
| 100 | O1-09-01: IMPACT OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE IN CLINICAL PRACTICE: A MULTICENTRIC STUDY. , 2014, 10, P146-P147. | | 0 |
| 101 | P2-113: CSF AMYLOID-Î² 42/40 RATIO IN CLINICAL SETTINGS: A MULTICENTRIC STUDY. , 2014, 10, P512-P512. | | 0 |
| 102 | CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037097. | 0.4 | 0 |
| 103 | Memory assessment in illiterate patients: The diagnostic value of the TNI 93. Alzheimer's and Dementia, 2020, 16, e042059. | 0.4 | 0 |
| 104 | Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, e044711. | 0.4 | 0 |
| 105 | Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 106 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 107 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 108 | Title is missing!. , 2020, 17, e1003289. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|----|-----------|
| 109 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 110 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 111 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 112 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 113 | Title is missing!. , 2020, 17, e1003147. | | 0 |
| 114 | Title is missing!. , 2020, 17, e1003147. | | 0 |
| 115 | Title is missing!. , 2020, 17, e1003147. | | 0 |
| 116 | Title is missing!. , 2020, 17, e1003147. | | 0 |
| 117 | Title is missing!. , 2020, 17, e1003147. | | 0 |